ALUMIS INC. (ALMS): Results of Operations and Financial Condition
ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alms-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements – ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new stand
How this was made
The 30-second read
Why it matters
The most tradable elements are the reiterated regulatory and clinical timeline (NDA submission in Q4 2026, potentially pivotal Phase 2b topline in Q3 2026) and the stated cash runway into Q4 2027, which together affect probability-weighted valuation and near-term risk appetite.
Market read
A late-stage biotech milestone update with explicit timing for SLE topline and psoriasis NDA submission, plus cash runway guidance, can drive trading around probability-weighted clinical/regulatory outcomes.
What to watch
The article does not provide new SLE efficacy numbers, only timing; market reaction may depend on whether ONWARD3 durability translates to SLE endpoints in LUMUS.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 covering Q2 2026 financial results and clinical/pipeline milestones for envudeucitinib (TYK2) and A-005.
Ticker impact
Alumis reports Q2 2026 results and reiterates plans to submit an envudeucitinib NDA for plaque psoriasis in Q4 2026.
Bias upward into Q3 2026 as traders price in SLE readout optionality, with volatility around trial and regulatory milestones.
The filing discloses specific clinical milestones (Q3 2026 LUMUS topline, Q4 2026 NDA submission) plus cash runway into Q4 2027, which can shift risk/reward for a late-stage biotech.
Market effects
Reinforces investor focus on TYK2 oral franchise narratives and interferon-pathway targeting in immune-mediated diseases.
Limited direct regional impact; primarily US biotech sentiment.
Moderate, as psoriasis and SLE development timelines can influence global TYK2 competitive positioning and trial expectations.
Counterpoint
Strategic alternatives for the lonigutamab program and a large impairment loss highlight portfolio risk, which can temper enthusiasm despite TYK2 progress.
Key entities
- companyAlumis Inc.
Late-stage biopharmaceutical developing envudeucitinib (TYK2) and A-005, reporting Q2 2026 results and milestone timing.
- drug_programenvudeucitinib
Oral selective TYK2 inhibitor in Phase 3 for plaque psoriasis and Phase 2b for SLE, with NDA submission targeted for Q4 2026.
- drug_programA-005
CNS-penetrant TYK2 inhibitor advancing to a Phase 2 biomarker trial in Parkinson’s disease in 1H 2027.
- drug_programlonigutamab
Asset for which Alumis completed a strategic review and decided to explore strategic alternatives.
